WE CARE ABOUT RARE DISEASE PATIENTS

FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.

FDA approves Gamifant® (emapalumab), the first and only treatment for primary haemophagocytic lymphohistiocytosis (HLH)